UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 4, 2005
                                                  ------------------------------

                           Interleukin Genetics, Inc.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                   000-23413                 94-3123681
- --------------------------------------------------------------------------------
(State or other jurisdiction       (Commission                (IRS Employer
         of incorporation)         File Number)             Identification No.)


              135  Beaver Street Waltham, MA                      02452
- --------------------------------------------------------------------------------
         (Address of principal executive offices)              (Zip Code)

Registrant's telephone number, including area code (781) 398-0700
                                                   -----------------------------

                                (not applicable)
- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)

     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

|_|  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

|_|  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))





Item 2.02 Results of Operations and Financial Condition.

     On November 4, 2005,  Interleukin Genetics,  Inc. issued a press release to
report its  consolidated  financial  results for the quarter ended September 30,
2005. A copy of the earnings press release is being  furnished  pursuant to this
Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

          (c)  The following exhibit is furnished with this report:

Exhibit No.    Description
- -----------    -----------

   99.1        Earnings Press Release dated November 4, 2005.





                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                      INTERLEUKIN GENETICS, INC.


Date: November 4, 2005                By:      /s/ PHILIP R. REILY
                                               ---------------------------------
                                               Philip R. Reilly
                                               Chief Executive Officer